Cargando…
Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain
Incentives contribute to the proper functioning of the broader contracts that regulate the relationships between health systems and professionals. Likewise, incentives are an important element of clinical governance understood as health services’ management at the micro-level, aimed at achieving bet...
Autores principales: | Lobo, Félix, Río-Álvarez, Isabel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004168/ https://www.ncbi.nlm.nih.gov/pubmed/33809934 http://dx.doi.org/10.3390/ph14030283 |
Ejemplares similares
-
Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019
por: García-Goñi, Manuel, et al.
Publicado: (2021) -
Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary
por: Shubow, Sophie, et al.
Publicado: (2022) -
Incentives and performance: governance of research organizations
por: Welpe, Isabell M, et al.
Publicado: (2015) -
Healthcare professionals’ perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study
por: Aladul, Mohammed Ibrahim, et al.
Publicado: (2018) -
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)